Franklin Resources Inc. Increases Stock Holdings in Bruker Corporation $BRKR

Franklin Resources Inc. lifted its stake in Bruker Corporation (NASDAQ:BRKR) by 317.7% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 2,309,404 shares of the medical research company’s stock after purchasing an additional 1,756,460 shares during the quarter. Franklin Resources Inc.’s holdings in Bruker were worth $108,796,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of BRKR. Los Angeles Capital Management LLC purchased a new position in shares of Bruker in the 4th quarter worth approximately $26,000. Allworth Financial LP boosted its holdings in shares of Bruker by 40.6% in the 3rd quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock worth $29,000 after purchasing an additional 257 shares during the period. Parallel Advisors LLC boosted its holdings in shares of Bruker by 121.0% in the 4th quarter. Parallel Advisors LLC now owns 875 shares of the medical research company’s stock worth $41,000 after purchasing an additional 479 shares during the period. Covestor Ltd boosted its holdings in shares of Bruker by 304.6% in the 4th quarter. Covestor Ltd now owns 1,416 shares of the medical research company’s stock worth $67,000 after purchasing an additional 1,066 shares during the period. Finally, CWM LLC boosted its holdings in shares of Bruker by 49.8% in the 4th quarter. CWM LLC now owns 1,631 shares of the medical research company’s stock worth $77,000 after purchasing an additional 542 shares during the period. Hedge funds and other institutional investors own 79.52% of the company’s stock.

Bruker Price Performance

Shares of BRKR stock opened at $54.92 on Thursday. Bruker Corporation has a twelve month low of $28.53 and a twelve month high of $64.54. The company has a current ratio of 1.55, a quick ratio of 0.72 and a debt-to-equity ratio of 0.67. The stock has a fifty day simple moving average of $43.87 and a two-hundred day simple moving average of $43.73. The stock has a market capitalization of $8.36 billion, a price-to-earnings ratio of -228.83, a P/E/G ratio of 1.83 and a beta of 1.31.

Bruker (NASDAQ:BRKR) last issued its quarterly earnings data on Wednesday, May 6th. The medical research company reported $0.31 earnings per share for the quarter, topping analysts’ consensus estimates of $0.23 by $0.08. The firm had revenue of $823.40 million during the quarter, compared to analysts’ expectations of $795.62 million. Bruker had a positive return on equity of 11.60% and a negative net margin of 0.65%.The firm’s quarterly revenue was up 2.7% on a year-over-year basis. During the same period in the prior year, the business posted $0.47 EPS. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. On average, analysts predict that Bruker Corporation will post 2.12 EPS for the current fiscal year.

Bruker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 7th. Investors of record on Monday, June 22nd will be paid a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date is Monday, June 22nd. Bruker’s dividend payout ratio is -83.33%.

Analysts Set New Price Targets

BRKR has been the subject of a number of recent analyst reports. Wolfe Research initiated coverage on Bruker in a report on Monday, June 1st. They set a “peer perform” rating for the company. Wall Street Zen upgraded Bruker from a “hold” rating to a “buy” rating in a report on Saturday, May 9th. Guggenheim dropped their price objective on Bruker from $58.00 to $50.00 and set a “buy” rating for the company in a report on Monday, March 30th. Weiss Ratings upgraded Bruker from a “sell (d)” rating to a “sell (d+)” rating in a report on Wednesday, June 3rd. Finally, The Goldman Sachs Group dropped their price objective on Bruker from $40.00 to $35.00 and set a “sell” rating for the company in a report on Friday, February 13th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, six have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $51.31.

Insider Buying and Selling at Bruker

In related news, VP Mark Munch sold 2,000 shares of the company’s stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $39.90, for a total transaction of $79,800.00. Following the completion of the sale, the vice president directly owned 128,443 shares in the company, valued at $5,124,875.70. This represents a 1.53% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. 27.20% of the stock is owned by company insiders.

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.